Scienmag

JUNE 18, 2025

This discovery emphasizes the gene’s influence on cellular growth regulation and differentiation pathways within prostate tissue. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). From a clinical perspective, these mutations provide actionable insights.

Genetics

XTalks

DECEMBER 18, 2024

Currently, the standard treatment for CAH involves glucocorticoids, which replace cortisol and help regulate hormone levels. Trial data for both the pediatric and adult trials were published in The New England Journal of Medicine. Crenessity marks the third approved drug for Neurocrine. billion in revenue by 2024.

Genetics

Pharmaceutical Technology

JUNE 26, 2025

While regulators are responding by establishing guidelines and promoting collaboration with industry stakeholders, challenges remain, particularly regarding ethical implications of AI technologies in healthcare. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

Drugs

Pharmaceutical Technology

JUNE 19, 2025

By GlobalData Learn more about Strategic Intelligence Draig was established through a partnership between Cardiff University’s Medicines Discovery Institute and SV Health Investors. Can pharma tariffs “Make America Manufacture Again”? Stay proactive with real-time data and expert analysis.

Clinical Trials

XTalks

JULY 23, 2025

Neuroscience is entering a new chapter shaped by advances in genetic medicine, more adaptive regulatory frameworks and deeper insight into the biology of neurological disorders. More than 300 million people around the world are affected by rare diseases, and nearly half of these involve the nervous system. It’s not about checking boxes.

Gene Therapy

Pharmaceutical Technology

JUNE 12, 2025

However, few medicines are approved for ATTR-wt. GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm, with the newly approved medicine likely to steal the majority of the patient share from competitors. Can pharma tariffs “Make America Manufacture Again”?

Clinical Trials

Pharmaceutical Technology

JUNE 25, 2025

In June 2024, Sanofi invested $40 million in Vigil Neuroscience, securing an exclusive right of first negotiation to license VG-3927. Can pharma tariffs “Make America Manufacture Again”? GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.

Clinical Trials

Pharmaceutical Technology

JUNE 19, 2025

Robert Barrie June 19, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Both Kisunla and Leqembi are both approved by the Medicines and Healthcare products Regulatory Agency (MHRA), meaning they will still be available privately. Can pharma tariffs “Make America Manufacture Again”?

Drugs

Pharmaceutical Technology

JUNE 24, 2025

Can pharma tariffs “Make America Manufacture Again”? Data Insights The gold standard of business intelligence.

Manufacturing

XTalks

FEBRUARY 12, 2025

LIB Therapeutics has announced that the FDA has accepted its Biologics License Application (BLA) for lerodalcibep, a novel investigational treatment aimed at reducing low-density lipoprotein cholesterol (LDL-C) in a broad patient population.

Cardiology

Pharmaceutical Technology

JUNE 18, 2025

With the launch, Genomics claims its test is the first product in the country to be registered with the Medicines and Healthcare products Regulatory Agency (MHRA) and carry the UK Conformity Assessed (UKCA) mark, combining genetic testing and clinical data to enable prediction and prevention.

Genomics

Pharmaceutical Technology

JUNE 12, 2025

SB-007 has received clearance from the Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) to enter clinical development. Can pharma tariffs “Make America Manufacture Again”? GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Gene Therapy

Pharmaceutical Technology

JUNE 18, 2025

Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational oral medicine, zagociguat, for mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), a rare mitochondrial disease. Can pharma tariffs “Make America Manufacture Again”?

Clinical Trials

Pharmaceutical Technology

JUNE 6, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Drugs

Bio Pharma Dive

JUNE 23, 2025

Understanding GLP-1 drugs GLP-1, or glucagon-like peptide-1 receptor modulators, mimic natural hormones that regulate insulin and appetite. As these therapies develop, they exemplify the dynamic interplay between medicine, technology, and society’s evolving health needs.

Gene Therapy

Pharmaceutical Technology

JUNE 20, 2025

Sanofi recently agreed to purchase Blueprint Medicines at an equity valuation of $9.1bn in a strategic move to strengthen its portfolio in the immunology domain with the addition of therapies for rare diseases. Can pharma tariffs “Make America Manufacture Again”? Sign up for our daily news round-up!

Vaccination

XTalks

MARCH 19, 2025

In doing so, it helps regulate calcium and phosphate more naturally, potentially limiting urinary calcium excretion and supporting kidney and bone health. AstraZeneca anticipates the first Phase III data for seven new medicines in 2025, along with key indication opportunities for existing therapies.

Trials

Pharmaceutical Technology

JUNE 12, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

Pharmaceutical Technology

JULY 21, 2025

From understanding disease development and progression to designing ligands with optimal binding affinity, structural biology underpins modern medicinal chemistry. These are important features that often determine binding kinetics, allosteric regulation and resistance mutations, all crucial for precision drug design.

Protein

Bio Pharma Dive

JULY 22, 2025

Published July 22, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Replimune Group and Johnson & Johnson, as well as updates from Omega Funds, iTeos Therapeutics and Roche that you may have missed. . — and European life sciences companies.

Gene Therapy

Pharmaceutical Technology

JUNE 10, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

Pharmaceutical Technology

JUNE 19, 2025

The US regulator has granted orphan drug, fast track and rare paediatric drug designations to the therapy. Can pharma tariffs “Make America Manufacture Again”? Actio is progressing this therapy through the healthy volunteer phase of a Phase I trial and aims to move into a Phase Ib trial in individuals with TRPV4+ CMT2C in 2026.

Clinical Trials

Pharmaceutical Technology

JUNE 25, 2025

Medera and its subsidiary Novoheart have collaborated with scientists at the University of California San Diego School of Medicine and Mayo Clinic to develop mini-heart models for hypoplastic left heart syndrome (HLHS). Can pharma tariffs “Make America Manufacture Again”? Credit: shisu_ka/Shutterstock.

Clinical Trials

Pharmaceutical Technology

JUNE 6, 2025

Following a positive opinion received in April 2025 from the European Medicines Agency’s Committee for Medicinal Products for Human Use, Japan-based eye health company Santen obtained the rights to commercialise the therapy under the brand name Ryjunea in Europe and the Middle East and Africa region.

Clinical Trials

Pharmaceutical Technology

JUNE 25, 2025

By addressing two central drivers of the underlying type 2 inflammation that contributes to bullous pemphigoid, Dupixent is the first targeted medicine to allow patients the potential to achieve sustained remission and reduce itch. Can pharma tariffs “Make America Manufacture Again”?

FDA Approval

Pharmaceutical Technology

JUNE 18, 2025

Should any assets identified by MAT be acquired by Lisata, GATC is entitled to receive licensing fees on a per-project basis. Can pharma tariffs “Make America Manufacture Again”? Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Development

Pharmaceutical Technology

JUNE 25, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

Pharmaceutical Technology

JUNE 23, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Gene Therapy

Pharmaceutical Technology

JUNE 12, 2025

The research collaboration and exclusive worldwide license agreement will see Deep Apple tasked with discovering and optimising drug candidates directed at a non-incretin G protein-coupled receptor target. Can pharma tariffs “Make America Manufacture Again”?

Research

Pharmaceutical Technology

JUNE 25, 2025

Fresh off a regulatory victory for a new HIV product, Gilead is shifting focus to the oncology space – signing a deal worth up to $750m to license a solid tumour treatment candidate from Kymera Therapeutics. Can pharma tariffs “Make America Manufacture Again”? Credit: Sundry Photography via Shutterstock.

Drugs

Pharmaceutical Technology

JUNE 25, 2025

Find out more Kennedy defended his choices, stating that the new committee members are dedicated to evidence-based medicine and will demand rigorous safety and efficacy data before making new vaccine recommendations. Can pharma tariffs “Make America Manufacture Again”?

Vaccination

Pharmaceutical Technology

JUNE 16, 2025

The partnership aims to accelerate the progression of candidate mRNA medicines from research to clinical proof-of-concept. Can pharma tariffs “Make America Manufacture Again”? Go deeper with GlobalData Reports NPVM: Moderna Incs mRNA-1010 Reports NPVM: Moderna Incs mRNA-1647 Data Insights The gold standard of business intelligence.

Manufacturing

Pharmaceutical Technology

JUNE 27, 2025

Thank you for subscribing View all newsletters from across the GlobalData Media network.

FDA Approval

Pharmaceutical Technology

JUNE 19, 2025

After that, it will be about compliance and regulation, as we must ensure that all our processes adhere to pharma regulations. Regulation has not been done in a space environment before, so we recognise we’ve got some hurdles to jump through, but these conversations are starting and that is exciting.”

Clinical Trials

Pharmaceutical Technology

JUNE 9, 2025

Analysis includes innovative medicines with approved indications or indication extensions that were reimbursed since 2021. Factors assessed include the ratio of approved medicines to those that are reimbursed, volume of products reimbursed per year, and time to pricing and reimbursement. Patient profiles were counted distinctly.

Marketing

Pharmaceutical Technology

JUNE 23, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Manufacturing

Pharmaceutical Technology

JULY 1, 2025

The package would amend a number of regulations to better meet patients’ needs by addressing the security of supply and boosting innovation, according to an explainer by the European Council (EC), one of the three EU bodies that are now in discussions on this package. How will RFK Jr’s American dream for vaccines play out?

Pharma Packaging